Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.

@article{Bolhuis1992AdoptiveIO,
  title={Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.},
  author={Reinder L. H. Bolhuis and Cor H J Lamers and Swan Hoo Goey and A. M. M. Eggermont and J. Baptist M. Z. Trimbos and Gerrit J. Stoter and Antonio Lanzavecchia and E M di Re and Silvia Miotti and Francesco Raspagliesi},
  journal={International journal of cancer. Supplement = Journal international du cancer. Supplement},
  year={1992},
  volume={7},
  pages={78-81}
}
A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch… CONTINUE READING